<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00353457</url>
  </required_header>
  <id_info>
    <org_study_id>803437</org_study_id>
    <secondary_id>UPCC 09204</secondary_id>
    <nct_id>NCT00353457</nct_id>
  </id_info>
  <brief_title>Capecitabine,Oxaliplatin &amp; Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma</brief_title>
  <official_title>Phase II Study of Capecitabine, Oxaliplatin and Cetuximab Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study of induction chemotherapy (capecitabine, oxaliplatin and cetuximab&#xD;
      (erbitux)) followed by capecitabine, oxaliplatin, cetuximab and radiotherapy followed by&#xD;
      surgery followed by adjuvant capecitabine, oxaliplatin and cetuximab for locally advanced&#xD;
      resectable rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    new studies were finding that Erbitux was not beneficial&#xD;
  </why_stopped>
  <start_date type="Actual">February 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response</measure>
    <time_frame>After neoadjuvant treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sphincter function</measure>
    <time_frame>After surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of surgery</measure>
    <time_frame>At time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>From time of study entry until first documented relapse</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine, Oxaliplatin and Cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine, Oxaliplatin and Cetuximab</intervention_name>
    <description>Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>45 Gy in 25 fractions, 3-fraction boost 5.4 Gy</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed nonmetastatic, measurable, locally advanced (T3 or T4) rectal&#xD;
             adenocarcinoma&#xD;
&#xD;
          -  If available, tumor tissue must be sent for investigational immunohistochemical&#xD;
             evaluations of EGFR status&#xD;
&#xD;
          -  The distal border of the tumor must be at or below the peritoneal reflection (defined&#xD;
             a with 12 cm of the anal verge by proctoscopy)&#xD;
&#xD;
          -  Transmural penetration of the tumor demonstrated by CT + endorectal ultrasound or MRI&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  No prior chemotherapy, biologic therapy or radiation therapy&#xD;
&#xD;
          -  Age &gt;= 18 years old&#xD;
&#xD;
          -  Laboratory values: ANC &gt;= 1500/mm3; Platelets &gt;= 100,000/mm3; Hgb &gt;= 9 g/dL; Estimated&#xD;
             CrCl &gt; 50 mL/min; Serum bilirubin &lt;= 1.5 x ULN; AST and ALT &lt;= 3.0 x ULN; Negative&#xD;
             proteinuria based on dip stick reading&#xD;
&#xD;
          -  Patients must either be not of child bearing potential or have a negative pregnancy&#xD;
             test upon study enrollment. Patients must agree to continue contraception for 30 days&#xD;
             from the date of the last study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating woman. Women of childbearing potential with either a positive or&#xD;
             no pregnancy test upon study enrollment. Women/men of childbearing potential not using&#xD;
             a reliable and appropriate contraceptive method. Patients must agree to continue&#xD;
             contraception for 30 days from the date of the last study administration.&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Serious, uncontrolled, concurrent infection(s)&#xD;
&#xD;
          -  Concurrent use of chemotherapy not indicated in the study protocol or any other&#xD;
             investigational agents and patients who have received investigational drugs &lt; 4 weeks&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Prior therapy which specifically and directly targets the EGFR pathway.&#xD;
&#xD;
          -  Prior severe infusion reaction to a monoclonal antibody&#xD;
&#xD;
          -  Any prior therapy with Oxaliplatin&#xD;
&#xD;
          -  Prior pelvic irradiation for any reason&#xD;
&#xD;
          -  Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity&#xD;
             to 5-fluorouracil or known DPD deficiency&#xD;
&#xD;
          -  Treatment for other carcinomas within the last five years, except cured non-melanoma&#xD;
             skin and treated in-situ cervical cancer&#xD;
&#xD;
          -  Participation in any investigational drug study within 4 weeks preceding the start of&#xD;
             the study treatment&#xD;
&#xD;
          -  Major surgery within 4 weeks of the study treatment, without complete recovery&#xD;
&#xD;
          -  Known, existing uncontrolled coagulopathy&#xD;
&#xD;
          -  Unwillingness to give written informed consent&#xD;
&#xD;
          -  Unwillingness to participate or inability to comply with the protocol for the duration&#xD;
             of the study&#xD;
&#xD;
          -  Known allergy or hypersensitivity to platinum-containing drugs&#xD;
&#xD;
          -  Peripheral sensory neuropathy with functional impairment&#xD;
&#xD;
          -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung&#xD;
&#xD;
          -  Pleural effusions or ascites that causes respiratory compromise&#xD;
&#xD;
          -  Acute hepatitis or known HIV&#xD;
&#xD;
          -  Any of the following concurrent severe and/or uncontrolled medical conditions which&#xD;
             could compromise participation in the study: uncontrolled high blood pressure, history&#xD;
             of labile hypertension, or history of poor compliance with anti-hypertensive regimen;&#xD;
             unstable angina pectoris; symptomatic congestive heart failure; myocardial infarction&#xD;
             &lt; 6 months prior to randomization; serious uncontrolled cardiac arrhythmia;&#xD;
             uncontrolled diabetes; active or uncontrolled infection; impairment of&#xD;
             gastrointestinal function or GI disease that may significantly alter the absorption of&#xD;
             Capecitabine.&#xD;
&#xD;
          -  Evidence of CNS metastases or history of uncontrolled seizures, central nervous system&#xD;
             disorders or psychiatric disability judged by the investigator to be clinically&#xD;
             significant, precluding informed consent, or interfering with compliance of oral drug&#xD;
             intake.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel G Haller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James M Metz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of University of Pennsylvania</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 14, 2006</study_first_submitted>
  <study_first_submitted_qc>July 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2006</study_first_posted>
  <disposition_first_submitted>April 6, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 9, 2020</disposition_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjuvant therapy</keyword>
  <keyword>Rectal cancer</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Erbitux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

